Rehovot, Israel
September 1, 2020

Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announced that it has entered into a definitive agreement with ARK Investment Management, LLC (ARK Invest) and Alpha Capital Anstalt in connection with a registered direct offering of ordinary shares at a price per share of $1.70, for an aggregate cash consideration of $10 million. Of the aggregate investment amount, ARK Invest, a leading technology investment firm, specializing in thematic investing in disruptive innovation, will invest $7 million and Alpha Capital Anstalt will invest $3 million.

Evogene intends to use the net proceeds from the offering to further develop its and its subsidiaries' product pipelines, to further enhance and expand its computational predictive biology platform, and for working capital and general corporate purposes.

The offering is expected to close on or before September 3, 2020, subject to customary closing conditions.

The shares of common stock offered in the registered direct offering described above are being offered by Evogene pursuant to its shelf registration statement on Form F-3 (File No.333-240249) previously filed and declared effective by the Securities and Exchange Commission (the “SEC”) on August 10, 2020. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website. 

Website: http://www.evogene.com

Published: September 1, 2020